Sanofi (EPA: SAN)
France
· Delayed Price · Currency is EUR | Market Cap | 114.43B |
| Revenue (ttm) | 48.45B |
| Net Income (ttm) | 4.51B |
| Shares Out | 1.25B |
| EPS (ttm) | 3.59 |
| PE Ratio | 25.43 |
| Forward PE | 11.20 |
| Dividend | 3.76 (4.12%) |
| Ex-Dividend Date | n/a |
| Volume | 4,407,807 |
| Open | 90.89 |
| Previous Close | 91.50 |
| Day's Range | 89.93 - 91.62 |
| 52-Week Range | 84.93 - 106.14 |
| Beta | 0.42 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jan 30, 2025 |
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric ... [Read more]
Financial Performance
In 2023, Sanofi's revenue was 46.03 billion, an increase of 1.42% compared to the previous year's 45.39 billion. Earnings were 5.40 billion, a decrease of -35.49%.
Financial StatementsNews
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
These ten large-cap stocks were the best performers in the last week. Are they in your portfolio? Teva Pharmaceutical Industries Limited (NYSE: TEVA) stock escalated 33.88% after the company and Sano...
Sanofi to buy China rights to Cytokinetics lead asset
Cytokinetics (CYTK) stock is in focus as Sanofi (SNY) agrees to buy exclusive rights to its lead drug aficamten in Greater China. Read more here.
Cytokinetics Inc (CYTK) Announces Sanofi's Acquisition of Aficamten Rights in Greater China
Cytokinetics Inc (CYTK) Announces Sanofi's Acquisition of Aficamten Rights in Greater China
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
Jean-Paul Kress to join Sanofi's Board of Directors Paris, December 19, 2024. Sanofi's Board of Directors is pleased to welcome Jean-Paul Kress as an independent director as of January 1, 2025, replac...
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting analyst confidence and price targets. ... Full story available on Benzinga.co...
Sanofi and Teva Achieve Milestone in Ulcerative Colitis Treatment Study
Sanofi and Teva Achieve Milestone in Ulcerative Colitis Treatment Study
:max_bytes(150000):strip_icc():format(jpeg)/INV_SanofiBuilding_GettyImages-1290694995-7f37d2e53c624d76ad5ddd4a136279c4.jpg)
Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's
Teva Pharmaceuticals and Sanofi announced positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn's disease.
Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment
Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies.
Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment
Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies.
Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?
Teva and Sanofi's Phase 2b RELIEVE ... Full story available on Benzinga.com
Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?
On Tuesday, Teva Pharmaceutical Industries Ltd. TEVA and Sanofi SA's SNY Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn's disease (CD).
Sanofi's 340B Credit Proposal Draws Federal Warning For Statutory Violation
The Health Resources and Services Administration (HRSA) has warned Sanofi SA (NASDAQ: SNY) about its proposed credit model for certain outpatient drugs under the 340B program. HRSA asserts that the c...
BrightInsight Expands Global Digital Partnership with Sanofi to Build Drug Companion Apps for its Major Specialty Therapies
BrightInsight announced an expanded global digital partnership with Sanofi to build branded patient apps to drive adoption, adherence, and persistence.
Teva, Sanofi gain after mid-stage trial win for IBD therapy
Teva (TEVA) stock and Sanofi (SNY) stock jump after a mid-stage trial win for an experimental antibody therapy targeting inflammatory bowel diseases. Read more here.
Teva, Sanofi say drug to treat IBD met primary targets
Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and Crohn's disease showed it had met primary goals.
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease
Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease Primary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most co...
Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease
Primary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the h...
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease
Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease Primary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most co...
Press Release: Availability of the Q4 2024 Aide-mémoire
Availability of the Q4 2024 Aide-mémoire Paris, France – December 17, 2024 . Sanofi announced today that its Q4 2024 Aide-mémoire is available on the "Investors" page of the company's website: Fourth ...
Pharmaceutical leaders convene in Paris to unveil vaccine strategies
Pfizer, Sanofi, Moderna, GSK and Novavax confirmed their attendance to Euractiv. The post Pharmaceutical leaders convene in Paris to unveil vaccine strategies appeared first on Euractiv .
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults with non-r...
Gilead appoints Sanofi official Dietmar Berger as next chief medical officer
Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent Merdad Parsey, who prepares to leave early next year.
Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US First non-mRNA combination vaccine candidates that include two already licensed vac...
Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients New analysis from the IMROZ phase 3 study of Sarclisa-VRd demonstrated higher and sustained MR...
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP